Pharmaceuticals, Biotechnology and Life Sciences
LONDON, April 28, 2025 (GLOBE NEWSWIRE) — Axovia Therapeutics Ltd., a biotechnology company developing therapies to address the genetic causes…
PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent…
Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene…
NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…
Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profileAbpro and Celltrion have a strategic partnership for…
Zoldonrasib, a RAS(ON) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D…
STAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe…
Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025CORAL GABLES, Fla., April 27, 2025…
BEIJING, April 27, 2025 (GLOBE NEWSWIRE) — On April 25, 2025, the 66th (Spring 2025) National Pharmaceutical Machinery Exposition &…
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf…